Vitamin B 6 is present in our diet in many forms, however, only pyridoxal 5 0 -phosphate (PLP) can function as a cofactor for enzymes. The intestine absorbs nonphosphorylated B 6 vitamers, which are converted by specific enzymes to the active PLP form. 
| CHEMISTRY OF VITAMIN B 6 AND DIETARY SOURCES
Chemically, B 6 vitamers are derivatives of 2-methyl-3-hydroxy-5-hydroxymethyl-pyridine ( Figure 1 ). The C4 substituent is a hydroxymethyl (-CH 2 OH) group in pyridoxine, an aminomethyl (-CH 2 NH 2 ) group in pyridoxamine, and an aldehyde group (-CHO) in pyridoxal. vitamin B 6 for man are the diet 1 and the gut microbiota. In fruit and vegetables, B 6 is present principally as pyridoxine and its phosphate and glucoside. In meat and fish, it is mainly present as PLP and PMP. Synthesis of B 6 by the gut flora can make a significant contribution to our B 6 intake 2 and may explain why dietary B 6 deficiency is rare. It can occur in the first year of life when the gut flora is not fully established; in the 1950s, infants fed a milk formula that had been overheated during production developed seizures due to B 6 deficiency. 3 
| REACTIVITY
PLP is the only B 6 vitamer that acts as a cofactor for enzymes, a role that is enabled by its reactive aldehyde group. It undergoes a condensation reaction with the amino group of amino acids to produce a Schiff base which forms the basis of most of the enzyme catalyzed reactions for which PLP is required. 4 However, because of the reactivity of its aldehyde group PLP can be involved in other, unwanted reactions with macromolecules within the cell (a form of aldehyde or carbonyl stress) analogous to the unwanted reactions of reactive oxygen species. Reactions of PLP with amino groups of proteins can alter their structure 5 and at concentrations of 10 to 100 μM inhibit enzyme activity 6 and aldehydes can damage DNA leading to mutagenesis. 7 PLP can also react with small molecules 8, 9 including sulphydryl compounds such as cysteine resulting in the formation of thiazoliodines 10 and with sulfite producing a sulphonate. The aldehyde group of PLP can also react, via Knoevenagel condensation, with Δ 1 -pyrroline 5-carboxylate and Δ 1 -piperideine 6-carboxylate. This is the mechanism of PLP deficiency in ALDH7A1 (antiquitin) deficiency and hyperprolinaemia type II, respectively. 11, 12 Hence, the cell maintains intracellular levels of free PLP at approximately 1 μM to avoid any unwanted reactions occuring. 13 Consideration of the reactivity of the aldehyde group of PLP is important when treating patients with certain drugs. Drugs that can inactivate PLP include hydrazines (eg, isoniazid and hydralazine), sulphydryl compounds (eg, penicillamine), and substituted hydroxylamines (eg, cycloserine).
| REACTIONS CATALYZED BY PLP ENZYMES
The Enzyme Commission (http://www.chem.qmul.ac. uk/iubmb/enzyme/) lists more than 140 PLP-dependent activities, corresponding to~4% of all classified activities 14 ; about 70 of these occur in man. These reactions involve diverse pathways (Table S1 ) including amino acid and neurotransmitter metabolism, folate and 1-carbon metabolism, protein and polyamine synthesis, carbohydrate and lipid metabolism, mitochondrial function and erythropoiesis. The involvement of PLP in these pathways is often apparent in PLP deficiency states which can be associated with biochemical abnormalities, for example, raised plasma threonine and glycine or low cerebrospinal fluid γ-aminobutyric acid (CSF GABA) ( Table 1 ) although these are not always/only transiently present in some patients. 15 In humans, each holoenzyme contains PLP attached by a Schiff base link to the ε-amino group of a lysine residue at the active site. 4 The largest number of catalyzed reactions involve the transfer of PLP to produce a new Schiff base linkage with the amino group of an amino acid substrate. This increases the reactivity of the α, β, and γ carbons of the amino acid. Subsequent reactions at the α-carbon atom of the substrate include transamination, decarboxylation, racemisation, and elimination and replacement of an electrophilic group. Those occurring at the β-or γ-carbon atoms of amino acids include elimination or replacement. 4 PLP is also instrumental in the reaction catalyzed by glycogen phosphorylase (EC 2.4.1.1). The aldehyde group of PLP forms a Schiff base linkage to lysine 680. However, unlike most PLP-dependent enzymes the reaction catalyzed For PLP to enter the brain, it must dissociate from albumin and be dephosphorylated to pyridoxal at the blood-brain barrier (BBB). Dephosphorylation is accomplished by tissue nonspecific alkaline phosphatase (E.C.
3.1.3.1), an ectoenzyme tethered to cell membranes at the BBB by a glycophosphatidylinositol (GPI) anchor. Pyridoxal crosses the BBB, probably by facilitated diffusion, and is "trapped" as PLP in the brain cells and the choroid plexus by the action of pyridoxal kinase. 33 The choroid plexus appears to be the only organ besides the liver which is able to readily release PLP which explains the relatively high percentage of PLP in CSF (25% of total B 6 in rabbit 33 and 38% in man 34 PMP which can be converted back to PLP by PNPO (salvage pathway). 13 In man, the gene(s) and protein(s) responsible for uptake of B 6 vitamers have yet to be identified. In yeast, however, uptake of pyridoxine at the plasma membrane is mediated by Tpn1, a member of the purine-cytosine permease superfamily 35 and transport of PLP into the mitochondria is mediated by Mtm1p. 35 
| HOMEOSTASIS OF PLP CONCENTRATIONS IN CELLS AND BODY FLUIDS
Intracellular-free PLP concentrations are maintained at approximately 1 μM 13 to prevent inappropriate reactions ("aldehyde stress" or "carbonyl stress"). Several mechanisms are involved in maintaining low concentrations. Proteins that bind PLP and help maintain low-free PLP concentrations include glycogen phosphorylase in muscle, 36 hemoglobin in erythrocytes, 37 and albumin in plasma. 29 The enzymes that produce PLP (pyridoxal kinase and PNPO) are inhibited by PLP and in vitro studies suggest PLP is protected intracellularly by being transferred from these enzymes directly, to some PLP-dependent enzymes. [38] [39] [40] Free PLP can be degraded by phosphatases such as pyridoxal phosphatase (EC 3.1.3.74). Recently, it came to light that PROSC, an intracellular protein, renamed as PLP-binding protein (PLPBP), plays an important role in PLP homeostasis 41 and very recently it has been suggested that, in some species at least, free PLP levels might be affected by mutations in the NAD(P)HX epimerase enzyme 42 (EC 5.1.99.6).
| CAUSES AND CONSEQUENCES OF PLP DEFICIENCY

| Epilepsy
Because of the vital role of PLP in neurotransmitter metabolism, particularly synthesis of the inhibitory transmitter GABA, it is not surprising that inborn errors leading to PLP deficiency manifest as B 6 -responsive epilepsy, usually of early onset. This includes PNPO deficiency (a disorder affecting PLP synthesis and recycling; MIM #610090), disorders affecting PLP import into the brain (alkaline phosphatase deficiency [hypophosphatasia; MIM #241500] and GPI anchor synthesis defects), PLPBP deficiency (MIM #617290), a disorder likely due to abnormal intracellular PLP transport and disorders in which metabolites accumulate that inactivate PLP. This last mechanism occurs in the commonest cause of pyridoxine-dependent epilepsy (PDE), that is, ALDH7A1 deficiency (also known as α-aminoadipic semialdehyde [AASA] dehydrogenase or antiquitin deficiency; MIM #266100) and in hyperprolinaemia type II (deficiency of ALDH4A1; MIM #239500). ALDH7A1 deficiency results in build-up of an intermediate with a nucleophilic carbon atom-Δ 1 -piperideine 6-carboxylic acid (P6C) which reacts with PLP thereby inactivating it and resulting in PLP deficiency. 12 Accumulation of Δ 1 -pyrroline 5-carboxylic acid has a similar effect in hyperprolinaemia type II. 11 The clinical and biochemical features of disorders leading to B 6 -responsive seizures are summarized in Table 2 and some of these disorders are described in more detail below. Acquired epilepsy can occur when PLP synthesis is impaired, for example, by pyridoxal kinase inhibitors such as 4-O-methyl pyridoxine in Ginkgo nuts 43 or aminophylline. 44 Drugs such as isoniazid that can bind to and inactivate PLP may also cause B 6 -responsive seizures. 45 The pathogenesis of seizures in a brain with low PLP levels is likely to be multifactorial. The changes in brain chemistry are easier to study in mouse models or cultured neuronal cells than in human subjects. In a mouse model of hypophosphatasia, low levels of the inhibitory neurotransmitter, GABA, were demonstrated in 1995. 46 However, seizures in patients with hypophosphatasia are refractory to pro-GABAergic drugs and other experiments on the hypophosphatasia mouse show downregulation of P2X7 receptors and reduction of seizures by blockade of P2X7 receptors, suggesting the anticonvulsive effects of vitamin B 6 may be due to its capacity to block P2X7R receptors. 47, 48 Recent metabolomic profiling of the brains of mice with hypophosphatasia showed a complex range of abnormalities including low levels of GABA and another important neurotransmitter, adenosine, as well as abnormalities of metabolites involved in myelin synthesis (N-acetylaspartate [NAA] , N-acetylglutamate [NAG]), and in the methionine cycle and transsulfuration pathway (cystathionine and methionine). 49 Studies on vitamin B 6 -deprived Neuro-2a cells showed reduced synthesis of glycine, serine, and 5-methyl-tetrahydrofolate. The authors suggested that the low intracellular 5-methyl-THF concentrations observed in vitro may explain the favorable but so far unexplained response of some patients with ALDH7A1 deficiency epilepsy to folinic acid supplementation. 50 There are some dangers in extrapolating from animal models and cultured neuronal cells to human subjects with inborn errors affecting vitamin B 6 metabolism. Some conclusions on the causes of epilepsy due to PLP deficiency can perhaps be drawn from human inborn errors affecting specific PLP-dependent enzymes 51 (Table S1 ). Seizures are a major feature of disorders of the glycine-cleavage enzyme (nonketotic hyperglycinaemia), of phosphoserine aminotransferase deficiency and of mitochondrial glutamate oxalaoacetate amino transferase (GOT2) deficiency. 52 are also common in adults with untreated cystathione β-synthase deficiency (homocystinuria). In aromatic amino acid decarboxylase deficiency, the clinical picture is dominated by hypotonia, dystonia, and oculogyric crises and it has been suggested that some of the paroxysmal involuntary movements observed in PNPO deficiency might also be due to impaired dopaminergic neurotransmission. 54 
| Peripheral neuropathy
In adults, PLP deficiency most commonly causes peripheral neuropathy. It can be seen in individuals treated with drugs that form a complex with PLP and inactivate it such as penicillamine, hydralazine, isoniazid, and cycloserine. We speculate that mechanisms protecting the brain from PLP deficiency are developed after infancy so that beyond this age the major effect is seen on peripheral nerves.
| Systemic manifestations
PNPO-, ALDH7A1-, and PLPBP-deficiency in their most severe forms (neonatal presentations) can have other expected consequences including anemia, lactic acidosis, and hypoglycemia. Isoniazid over-dosage causes lactic acidosis.
| DETECTING B 6 -DEPENDENT EPILEPSY IN NEONATES
ALDH7A1 deficiency, PNPO deficiency, PLPBP deficiency, and hypophosphatasia can all present with antiepileptic drug resistant seizures (often myoclonic) in the first days of life. Although biomarkers and/or DNA analysis can provide fairly rapid diagnosis of these disorders, management of therapy-resistant seizures in the newborn is urgent and warrants an early standardized B 6 trial ( Figure 3 ). 55 Figure 3 .
In the first description of PDE, Hunt et al 56 described
complete control of seizures for 21 months with just 2 mg/day of pyridoxine. Over the ensuing years, the dose of pyridoxine used to treat PDE was gradually increased. One 10-year-old child with PDE, whose school performance was deteriorating showed a dramatic increase in intelligence quotient (IQ) when his pyridoxine dose was increased from a total of 50 to 150 mg/day. Subsequent testing of five other cases suggested some increase in IQ on increasing the dose from 5 mg/kg/d but no further increase was observed beyond 15 mg/kg/d. 57 These children were not characterized genetically and while it is likely that they had ALDH7A1 deficiency, the most prevalent form of PDE, we cannot be certain. Current guidelines suggest that total daily pyridoxine doses should, wherever possible not exceed 200 to 300 mg 55 and be divided into two single doses to avoid excess B 6 vitamer concentrations. Patients who experience break-through seizures during febrile infections while on pyridoxine, may receive a double daily dose for the first 3 days of future febrile illnesses. 55 For long-term treatment there is no evidence on the optimal pyridoxine dose to be used. In experimental animals, doses of pyridoxine >50 mg/kg/d cause ataxia, peripheral neuropathy and muscle weakness. Histological examination demonstrates widespread neuronal damage with loss of myelin and degeneration of sensory fibers in peripheral nerves, the dorsal columns of the spinal cord and descending tract of the trigeminal nerve. 58, 59 In human adults, peripheral neuropathy has rarely occurred at total doses <200 mg/d. For most cases where peripheral neuropathy has been documented the total dose was >1000 mg/d. In a neuronal cell line (SHSY5Y), pyridoxine has been shown to induce expression of apoptosis genes and cause dose-dependent cell death. 60 The mechanism may involve inhibition of PLP enzymes by pyridoxine. For the treatment of classical PNPO deficiency and PLPBP deficiency with insufficient stabilization on pyridoxine there is no pharmaceutical grade PLP available. Where PLP has been used for treatment in Europe and North America, it is a chemical compound or nutraceutical product where the PLP content may not be as stated. 61 PLP, when in solution, may be rapidly degraded by light and/or oxygen with the formation of dimers or pyridoxic acid 5 0 -phosphate and other products, respectively. 61 Hence, when a liquid formulation is required each PLP dose should be prepared from a tablet or capsule and given without delay. Usual doses range from 30 to 50 mg/kg/d divided into four to six single dosages. In order to avoid potential side effects the lowest effective dose should be used and no weight adjustment be performed in cases of seizure freedom. Some children taking high doses of PLP have developed persistently raised transaminases with progression to cirrhosis 62 and hepatocellular carcinoma (unpublished observation). The cause remains uncertain; possibilities included aldehyde stress from PLP and pyridoxal, or toxicity of PLP photodegradation products. In the case of molecularly proven diagnosis of any form of vitamin B 6 -dependent epilepsy, parents and caregivers have to be informed that B 6 treatment is lifelong and that upon withdrawal, symptoms will re-occur; in some cases within a couple of hours, in others it may take several weeks.
| DEFICIENCY OF ALDH7A1
It was not until 2000 that findings of elevated pipecolic acid implied that PDE might be caused by a defect in the lysine catabolic pathway. 63 Subsequently, the defect in this pathway was identified as a deficiency of antiquitin (α-AASA dehydrogenase encoded by ALDH7A1), leading to the accumulation of α-AASA and its equilibrium partner, Δ1-piperideine-6-carboxylate (P6C) 12 ( Figure 4 ) and was shown to be identical to folinic acid-responsive seizures. 64 P6C inactivates PLP as indicated above. An elevated urinary AASA/creatinine ratio is a more reliable biomarker for this disorder than pipecolic acid although it is also elevated in some patients with molybdenum cofactor (MIM #252150) and sulfite oxidase deficiency (MIM #272300). 65 Simultaneous determination of sulfocysteine is therefore recommended to avoid diagnostic pitfalls. 66 Recently 6-oxo-pipecolate has been reported as a novel biomarker for this disorder. 67 Electroencephalogram (EEG) recording during i.v. administration of pyridoxine is not a reliable way of identifying patients. 68 The clinical spectrum of antiquitin deficiency extends from unspecific ventriculomegaly detected on foetal ultrasound, through abnormal foetal movements and a multisystem neonatal disorder, to onset of seizures and autistic features after the first year of life. 8, 9, 55 Clinical diagnosis can be challenging because: (a) there may be partial response to antiepileptic drugs (especially phenobarbitone); (b) in infants with multisystem pathology, response to pyridoxine may not be instant and obvious; and (c) structural brain abnormalities may coexist and be considered sufficient cause of epilepsy, whereas seizures are in fact a consequence of antiquitin F I G U R E 4 ALDH7A1 deficiency is a defect on the lysine catabolism pathway. Lysine catabolism occurs via two pathways; the saccharopine pathway (predominantly mitochondrial with two key steps within the cytosol) and the pipecolate pathway (predominantly cytosolic with a peroxisomal comparment). 121 Both pathways converge at 2-aminoadipic-6-semialdehyde (AASA) which is in a nonenzymatic equilibrium with 1-piperideine-6-carboxylate (P6C). The contribution of each pathway to lysine catabolism depends on the age of the individual and cell-type studied; studies in mice suggest that the saccharopine pathway is primarly reponsible for AASA/P6C prodcution. 80, 81 POX, L-pipecolate oxidase; PYRC, pyrroline-5-carboxylate reductase (three homologous genes exist; PYCR1 and PYCR2 localize to mitochondria and possibly with the outer mitochondrial membrane and PYCRL (aka PYCR3) is cytosolic 122, 123 deficiency. An overview of the clinical features of patients with ALDH7A1 deficiency is as detailed in Figure 5 (adapted from Karnebeek et al. 69 ). Phenotypes of 49 children with ALDH7A1 deficiency were summarized in a metaanalysis by van Karnebeek et al. 69 Since then the spectrum has been further extended, for example, ALDH7A1 deficiency presenting with adolescent onset epilepsy. 70 An increased incidence of structural brain abnormalities has been reported in individuals with mutations in ALDH7A1. 71, 72 Histologic analysis of PDE cortex in a deceased child revealed areas of abnormal radial neuronal organization consistent with type Ia focal cortical dysplasia. These malformations persist despite postnatal pyridoxine supplementation and probably contribute to neurodevelopmental F I G U R E 5 Overview of the symptoms reported in the literature for patients with ATQ deficiency. Red box: symptoms or biochemical features present in the majority of patients. All other boxes: symptoms present in the minority of patients. *Ultra-rare symptoms, reported in eight literature patients or fewer. 1 Unidentified peak in the HPLC chromatogram for CSF monoamine neurotransmitter analysis in ATQ deficiency patients. 2 Potentially normalize on pyridoxine therapy. 3 See van Karnebeek et al. 69 α-AASA, α-aminoadipic semialdehyde; ADHD, attention deficit hyperactivity disorder; ATQ, antiquitin; CC, corpus callosum; CSF, cerebrospinal fluid; GABA, gamma-aminobutyric acid; OCD, obsessivecompulsive disorder; P6C, L-Δ1-piperideine-6 carboxylate impairments. Serine racemase, a PLP-dependent enzyme, is involved in neuronal migration. 73 Coughlin et al 74 have recently published a comprehensive overview of 165 known ALDH7A1 pathogenic variants which includes the genotypes of 185 individuals. It is estimated that the carrier frequency of ALDH7A1 mutations is 1:127 and that the estimated incidence of ALDH7A1 deficiency is 1:64 352 live births. 74 Seizures of patients with ALDH7A1 deficiency are well controlled on pyridoxine monotherapy in about 90% of cases, however, at least 75% of children have intellectual disability (ID) and developmental delay (DD). The degree to which they have ID/DD does not correlate with treatment delay, pretreatment symptomatic interval, or duration taken to achieve seizure control. 74 Two add-on treatment options have been trialed in relatively small numbers of patients. The first approach is the lysine-restricted diet to lower potentially toxic AASA concentrations. The second is the use of arginine which competes with lysine in the process of transport thereby reducing its intestinal absorption and transport into the brain. van Karnebeek et al 75 reported the effect of a lysine restricted diet in seven patients with ALDH7A1 deficiency. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20% to 67% for plasma pipecolic acid, 13% to 72% for urinary AASA, 45% for plasma AASA, and 42% for plasma P6C. CSF data, available for one patient, showed decreases of 87% and 82% for pipecolic acid and AASA, respectively. Improvement in age-appropriate skills was observed in four of five patients showing prediet delays, and seizure control was maintained or improved in six of seven children. Mercimek-Mahmutoglu et al 76 reported add-on supplementation with L-arginine (400 mg/kg/day; 5 g three times a day) in a 12-year-old boy. CSF α-AASA was decreased by 57% and neuropsychological assessments revealed improvements in general abilities index from 108 to 116 and improvements in verbal and motor functioning after 12 months of therapy. "Triple therapy" (pyridoxine and arginine supplementation, lysine restriction) has been reported for nine patients. [77] [78] [79] Treatment reduced levels of biomarkers such as plasma AASA, P6C, pipecolic acid, and threonine and improved development. Optimum results were reported for patients where treatment was started early, however, larger cohorts and long-term data with neurocognitive testing are needed to provide robust data. When a formula low in lysine and tryptophan (as manufactured for treatment of glutaric aciduria type I) is used there is a potential risk of low plasma tryptophan leading to central serotonin deficiency. Other therapeutic strategies currently being investigated, although still some way from clinical translation, include antisense therapy and substrate reduction therapy. infant whose pre-PLP biochemistry suggested deficient PLP-dependent enzyme activities: low CSF concentrations of HVA and 5HIAA with raised CSF 3-methoxytyrosine and urinary vanillactate (indicating aromatic amino acid decarboxylase deficiency) and raised plasma threonine and glycine indicating defects in the PLP-dependent pathways for catabolism of these amino acids. Other patients with similar findings were identified and were shown to have PNPO mutations leading to reduced enzyme activity. 84 Subsequently, PNPO-deficient patients were identified who did not have the "typical" biochemical changes. 15 Untreated patients who survived the neonatal period had anemia and failure to thrive. 85 Treatment of PNPO deficiency was found to be more difficult than that of ALDH7A1 deficiency in that PNPO-deficient patients may require a dose of PLP every 6 hours to avoid an epileptic prodrome or frank seizures. Reports have emphasized the possibility of normal developmental outcome with early treatment. 86, 87 A summary of the clinical features of patients with PNPO deficiency are as detailed in Figure 6 . By 2014, it was clear that some patients with PNPO deficiency respond to treatment with pyridoxine and indeed PLP may aggravate seizures. 88, 89 Mills et al 88 identified
three groups of patients with PNPO mutations that had reduced enzyme activity: (a) those with neonatal onset seizures responding to PLP (n = 6); (b) one patient with infantile spasms (onset 5 months) responsive to PLP; and (c) patients with seizures starting under 3 months of age responding to pyridoxine (n = 8). Certain genotypes (R225H/C and D33V) appear more likely to result in seizures responsive to pyridoxine. Other mutations seem to be associated with infertility, miscarriage, and prematurity. To date 62 genetically confirmed PNPO-deficient patients have been reported with 27 different mutations in PNPO [90] [91] [92] [93] [94] [95] (Table 3) . R116Q, initially thought to be a polymorphism due to its prevalence in the general population and segregation in some instances with other known pathogenic PNPO homozygous variants, has now been confirmed to be pathogenic, 90, 96 dramatically affecting erythrocyte PNPO activity. Five children have been reported that are homozygous for this variant and no other known pathogenic PNPO variants with seizure onset at 3 hours and 5 months 88 and 8 months, 24 months, and 3 years 2 months. 90 R116Q appears to result in a milder phenotype with four of five of the children presenting later and three of five having a good developmental outcome. The story is likely to be complicated, however, as not all individuals homozygous for R116Q-PNPO present with seizures. 96 While a low CSF PLP concentration is suggestive of a B 6 -dependent epilepsy disorder it may also be found in F I G U R E 6 Overview of the symptoms reported in the literature for patients with PNPO deficiency. Red box: symptoms or biochemical features present in the majority of patients. All other boxes: symptoms present in the minority of patients. *Ultra-rare symptoms, reported in three literature patients or fewer. 
epileptic encephalopathy with no specific diagnosis 97 and it should be noted that one PNPO-deficient child had PLP concentrations within the normal range. 91 A rapid LC-MS/MSbased dried blood spot assay, which measures PNPO enzyme activity, has been developed for diagnosis of PNPOdeficiency. 96 An elevated plasma pyridoxamine concentration can also be indicative of this disorder irrespective of vitamin B 6 treatment.
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| CONGENITAL HYPOPHOSPHATASIA DUE TO ALPL MUTATIONS
There is a very wide spectrum of disease caused by ALPL (TNALP, TNAP, TNSALP) mutations (hypophosphatasia) from skeletal hypomineralization and deformity detected in utero to presentation with premature loss of deciduous and/or permanent teeth. Only patients with the most severe neonatal form present with seizures in the neonatal period that can precede the detection of bone disease.
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Bone X-rays show features similar to rickets. Plasma alkaline phosphatase is below the normal range but it is important to compare to the correct age range. Urinary phosphoethanolamine is elevated. Plasma PLP and PLP/pyridoxal ratio are elevated (even prior to pyridoxine supplementation). 102 There may be biochemical evidence of intracellular PLP deficiency, for example, increased excretion of vanillactate.
In some neonates with CHP, seizures are antiepileptic drug-resistant and respond dramatically to pyridoxine. 103 However, in other cases, there is only a modest transient response to pyridoxine and the encephalopathy is fatal. 104 Most neonates and infants with severe CHP have severe restrictive thoracic deformity and most die of respiratory failure. Recently enzyme replacement therapy (ERT) that treats the bone disease has become available. 105 ERT reduces the plasma PLP concentration to a normal or mildly elevated level and the PLP-to-PL ratio to mildly reduced or low-normal levels.
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There are several reports of subacute brainstem degeneration in patients with CHP both on and off pyridoxine treatment. One hypothesis is that this is due to toxicity of very high extracellular PLP levels. 104 It is considered unlikely that ERT will be able to avoid this deleterious manifestation due to its inability to cross the BBB. It should be noted that the TNSALP protein is anchored at the BBB to GPI anchors. Inborn errors of metabolism causing deficiency of the proteins responsible for GPI anchor processing (eg, PIGO [MIM 614730]; PIGE [MIM 610274]) can occasionally lead to brain PLP deficiency and B 6 -responsive seizures. 106 
| HYPERPROLINAEMIA TYPE II
In hyperprolinaemia type II, mutations in ALDH4A1 lead to a deficiency of pyrroline 5-carboxylate (P5C) dehydrogenase which catalyzes the second step in proline catabolism. P5C can react with PLP and inactivate it. 11 Plasma proline is markedly elevated (often >1000 μM) and P5C can be detected in the urine by its color reaction with ortho-aminobenzaldehyde. Urine organic acid analysis may show the presence of pyrrole-2-carboxyglycine. 107 Only about 50% of individuals with HP2 develop seizures, onset of which is usually in infancy or childhood rather than in the first few days of life. The seizures can often be triggered by fever and controlled by antiepileptic drugs; B 6 -dependency is not as evident as in deficiencies of ALDH7A1, PNPO, and PLPBP. In the case reported by Farrant et al, 11 urine obtained during the admission with prolonged seizures contained excess xanthurenic acid indicating PLP deficiency.
In the series reported by van de Ven et al, 108 all patients showed seizures and significant behavioral problems, including anxiety and hallucinations and all had low plasma PLP levels. The clinical course was nonprogressive and independent of the B 6 concentration and B 6 therapy.
| PYRIDOXAL PHOSPHATE-BINDING PROTEIN (PROSC) DEFICIENCY
To date 15 patients with PLPBP-deficiency have been reported (Table 2 ). In 2016, Darin et al 41 reported seven children with pathogenic variants in proline synthetase cotranscribed homolog (bacterial), PROSC, which encoded a PLP-binding protein of hitherto unknown function. Pretreatment cerebrospinal fluid samples showed low PLP concentrations and evidence of reduced activity of PLP-dependent enzymes. However, cultured fibroblasts showed excessive PLP accumulation. The clinical picture was dominated by the seizure disorder (three of seven had intrauterine seizures, six of seven had seizures on day 1 of life, one of seven did not present until 1 month of age). However, systemic features (anemia, enterocolitis, electrolyte abnormalities) were sometimes present in the neonatal period. The birth head circumference was ≤ninth centile in four of seven. Brain MRI scans in early infancy showed global underdevelopment of the cortex (broad gyri and shallow sulci) and sometimes periventricular cysts, and later scans showed underdevelopment of white matter. Acquired microcephaly was present in six of seven and all had some degree of DD. Plecko et al 109 confirmed that PROSC (PLPBP) deficiency was a cause of PDE but the four patients identified had a milder disease: no intrauterine seizures, neonatal onset of seizures on days 3 to 9, only one of four with burst suppression on EEG (compared to five of seven) no microcephaly, normal MRI scans and normal development in three of four. Recently, Shiraku et al 110 have also identified four patients with PLPBP deficiency while screening a cohort of 700 patients with childhood onset epileptic encephalopathies. Seizures responded to treatment with pyridoxine for three of four patients and with PLP for one of four. Two of these children presented with seizures after 1 month of age (3 months and 34 days). Birth head circumference was normal but acquired microcephaly was reported for two of four. Similar to the first cohort of PLPBP-deficient patients described, all of these patients had some degree of ID.
| B 6 TREATMENT OF PLP-ENZYMOPATHIES
Binding of PLP to apoenzymes is obviously essential for the catalytic function of the enzyme but it may also be important for correct folding of the protein and targeting it to the right organelle. In individuals with primary hyperoxaluria type I (alanine glyoxylate transaminase [AGT] deficiency; MIM #259900), binding of PLP can prevent the build-up of AGT monomers which inappropriately target to the mitochondria. 111 Thus, PLP can act as a chaperone as well as requiring a chaperone (PLPBP) itself. It is beyond the scope of this review to list all PLP-enzymopathies that might respond to pyridoxine supplementation, however, five important disorders in which it should always be tested are cystathionine β-synthase deficiency (classical homocystinuria; MIM #613381), δ-amino laevulinic acid synthase-2 deficiency (X-linked sideroblastic anemia; MIM #300751), primary hyperoxaluria type I (MIM #259900), hyperornithinaemia with gyrate atrophy of the choroid and retina (MIM #258870), and aromatic amino acid decarboxylase deficiency (MIM #608643). 51 Recently, a patient with mutations in GOT2 encoding the mitochondrial glutamate oxaloacetate transaminase (EC 2.6.1.1) has been described. The patient presented with serine-and vitamin-B 6 -responsive epileptic encephalopathy, profound psychomotor delay and spastic paraparesis.
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| CONCLUSIONS AND FUTURE RESEARCH
• Most neonates with epileptic encephalopathy who respond dramatically to treatment with pyridoxine or pyridoxal phosphate can now be shown to have ALDH7A1 (antiquitin) deficiency, PNPO deficiency, or PLPBP deficiency.
• The challenge for the future in ALDH7A1-deficiency is to try and ensure that as few children as possible have learning difficulties. There may be a role for prenatal treatment to prevent brain structural malformations, consideration needs to be given to optimal pyridoxine dose and preliminary studies of dietary lysine restriction and arginine supplementation are encouraging.
• Some individuals can have a normal neurodevelopmental outcome, as is the case in 25% of patients with ALDH7A1 deficiency and in cases of PNPO deficiency which received prompt diagnosis and treatment with pyridoxine or pyridoxal phosphate.
• For subjects whose seizures cannot be controlled by pyridoxine and require pyridoxal phosphate, we need to understand why some develop abnormalities of liver function tests leading to cirrhosis and occasionally hepatocellular carcinoma and strive for improved methods of treatment.
• There are still big gaps in our understanding of PLP homeostasis: unidentified transporters, ill-defined regulation of expression of enzymes and transporters; the exact mechanism by which the cell gets PLP to holoenzymes while keeping free PLP levels low.
• There remain many subjects, either undiagnosed or with other genetic epilepsies, whose epilepsy is reduced in frequency and severity by vitamin B 6 treatment. We need to understand how this works. Do these subjects have more subtle defects in vitamin B 6 
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